Reports

At Medical Research Collaborative (MRC), the brunt of our time is spent researching, debating, vetting, writing, editing, and then ultimately disseminating comprehensive research reports to our Data Partners, while continuously monitoring/updating Data Partners on developments of target companies covered.

Bespoke Reports are compiled by request of interested parties, and become the co-ownership of such parties (MRC reserves the right to disseminate any/all commissioned Bespoke Reports to its Data Partners or the public, but not before a minimum time-period has elapsed; typically 30 days). These parties may copy, share, print, and disseminate such reports at will. However, certain of our reports will also find their way into this section and become available for public purchase and/or download.


Privacy

  • Client confidentiality is imperative to us; your identity and/or the identity of the firm you represent is kept strictly confidential. Please see our Privacy Notice for more information.

Refund Policy

  • As the content of our research contained within each report is considered proprietary information, and the viewing of a report containing our research equivalent to using that report, we do not issue refunds; therefore, all sales are final.

Terms of Use


For more information, please see our FAQ section. We may also be contacted directly. 


DISCLAIMER

The information contained in any and all research reports written, edited, and/or assembled by Medical Research Collaborative, LLC ("MRC") does not, and is not intended to, constitute legal or medical advice, and is for informational purposes only. In addition, we do not warrant or guarantee the success of any investment decision you make for yourself or on behalf of your firm in reliance upon the content of our research; trade ideas/alerts disseminated to subscribers are not recommendations to buy, sell, avoid, or sell short any security, and are for informational purposes only; we recommend securing the services of a registered investment advisor (which we are not) and performing your own independent investigations before acting on information from us.


CEL-SCI: An Imminent Phase 3 Failure

CEL-SCI: An Imminent Phase 3 Failure

Available for free download (on right) is our comprehensive analysis on Cel-Sci Corp. (select "Add t..

$0.00

Executive Summary of Legal Analysis on Amarin, et al. v. Hikma, et al.

Executive Summary of Legal Analysis on Amarin, et al. v. Hikma, et al.

Following is an executive summary of a legal analysis on Case No.: 2:16-cv-02525-MMD-NJK by Medica..

$0.00

AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP

AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP

AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP   Summary Since having ..

$0.00

Showing 1 to 3 of 3 (1 Pages)